Search company, investor...

Predict your next investment

Venture Capital
casdincapital.com

Investments

196

Portfolio Exits

50

Funds

2

Partners & Customers

1

About Casdin Capital

Casdin Capital is an investment firm focused on the life sciences and healthcare industry.

Headquarters Location

1350 Avenue of the Americas Suite 1140

New York, New York, 10019,

United States

Want to inform investors similar to Casdin Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Casdin Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Casdin Capital in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing Casdin Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Casdin Capital in 5 CB Insights research briefs, most recently on Sep 19, 2022.

Latest Casdin Capital News

Orbital Therapeutics: $270 Million Raised To Unleash The Potential Of RNA Medicines

May 3, 2023

Orbital Therapeutics – a company that is focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease – announced the successful closing of $270 million Series A financing. The Series A funding round was led by ARCH Venture Partners, with participation from initial investors a16z Bio + Health and Newpath Partners, and new investors Abu Dhabi Growth Fund (ADG), Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems, and other undisclosed investors. Orbital Therapeutics is aiming to expand the applicability of RNA-based medicines across a range of human diseases, including in the areas of next-generation vaccines, immunomodulation, and protein replacement. And the company is building a first-in-kind RNA platform that integrates both established and emerging RNA technologies and delivery mechanisms. This platform was designed to extend the durability of Orbital’s novel RNA therapeutics, while also expanding their delivery to a wide range of cell types and tissues. Along with financing, Orbital announced the expansion of its leadership team with the appointments of Niru Subramanian as chief operating officer and Jonathan Piazza as the chief financial officer, who join Gilles Besin, Ph.D., chief scientific officer, and Dr. Ciaramella on the company’s executive leadership team. Subramanian brings 25 years of business and corporate development experience, including building new strategies and capabilities for high-growth organizations, leading multifunctional teams, managing partnerships and M&A transactions, and directing portfolio planning, alliance management, finance and operations. And Subramanian most recently served as chief operating officer at Rheos Medicines, and prior to that, was senior vice president, corporate development & business planning at Agios Pharmaceuticals, where she led several key initiatives including the $2 billion sale of Agios’ oncology business in December 2020. Earlier, Subramanian held several roles at Novartis Vaccines, including as vice president, head of Influenza Global Programs and at Novartis as vice president, Vaccines Business transition lead following the divestment of the business unit. Earlier in her career, she worked at The Boston Consulting Group in their healthcare practice area advising large and small biopharma companies on a variety of strategic and operational issues. Subramanian received a BS in computer science and engineering from the University of Pennsylvania and an MBA from the Harvard Business School. Piazza is a seasoned biotech executive and finance professional with more than 20 years of experience in biotech, healthcare investment banking, finance, and large pharma roles. He most recently served as CFO of Silverback Therapeutics and helped orchestrate its IPO, and later its reverse merger with ARS Pharma. As a healthcare banker at Goldman Sachs, Barclays Capital, and Lehman Brothers, Piazza has advised on approximately $100 billion in biopharma and life sciences financing and strategic transactions across both large and small companies. Previously, Piazza was a financial advisor at Smith Barney (now Morgan Stanley Smith Barney), and prior to that, he worked in engineering, development, and international marketing disciplines at Abbott Laboratories across multiple divisions of the company. Piazza earned a BS in chemical engineering from The Ohio State University and an MBA from the Haas School of Business at the University of California at Berkeley. KEY QUOTES: “In recent years, we have only just started to see the expansive potential RNA-based therapeutics may offer to the future of medicine and how we treat disease. Since our founding, we have been diligently focused on advancing our platform of RNA technologies to elucidate the most promising opportunities with our initial programs so we may reach patients as efficiently as possible. We are thrilled to have the backing of such an exceptional group of investors, whose support further enables the growth of our organization and the meaningful expansion of our platform and portfolio.” — Giuseppe Ciaramella, Ph.D., Orbital co-founder and CEO “Few companies can possess the know-how, technology and biologic insights to deliver on the full breadth of opportunity that RNA medicines could provide for patients. Orbital was founded and has been built to be that special company. We are pleased to partner with Orbital’s team of industry leaders and visionaries in drug development to help them achieve a bold mission of bringing forward the next generation of RNA-based medicines.” — Kristina Burow, managing partner at ARCH Venture Partners, co-founder and board director of Orbital “Key to our long-term success is having a team that not only brings experience, but also passion and drive for the work we are doing. Niru has an extensive background in driving corporate strategy and portfolio development for successful biotech and pharmaceutical companies, which is complemented by Jonathan’s successful history of leading financial organizations within the industry and guiding several strategic transactions while at top investment banks. Their collective expertise and dedication to create a company that can advance important new medicines for patients makes them ideal additions to our team, and they already have made tremendous early contributions to our company’s growth and capital raise. We are thrilled to have them on board.” — Dr. Ciaramella

Casdin Capital Investments

196 Investments

Casdin Capital has made 196 investments. Their latest investment was in Orbital Therapeutics as part of their Series A on April 4, 2023.

CBI Logo

Casdin Capital Investments Activity

investments chart

Casdin Capital Portfolio Exits

50 Portfolio Exits

Casdin Capital has 50 portfolio exits. Their latest portfolio exit was Structure Therapeutics on February 03, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/3/2023

IPO

$99M

Public

23

10/20/2022

IPO

$99M

Public

18

7/21/2022

IPO

$99M

Public

2

12/21/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/10/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/3/2023

10/20/2022

7/21/2022

12/21/2021

12/10/2021

Exit

IPO

IPO

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

23

18

2

10

10

Casdin Capital Fund History

2 Fund Histories

Casdin Capital has 2 funds, including Casdin Private Growth Equity Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/9/2020

Casdin Private Growth Equity Fund

$179M

1

2/28/2018

Casdin Venture Opportunities Fund

$99M

10

Closing Date

11/9/2020

2/28/2018

Fund

Casdin Private Growth Equity Fund

Casdin Venture Opportunities Fund

Fund Type

Status

Amount

$179M

$99M

Sources

1

10

Casdin Capital Partners & Customers

1 Partners and customers

Casdin Capital has 1 strategic partners and customers. Casdin Capital recently partnered with Codexis on November 11, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

11/24/2020

Partner

United States

Codexis And Casdin Capital Launch SynBio Innovation Accelerator

To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis , Inc. , they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 , including Codexis , Inc. ' expectations regarding its partnership with Casdin Capital and its investment in Arzeda Corp. .

3

Date

11/24/2020

Type

Partner

Business Partner

Country

United States

News Snippet

Codexis And Casdin Capital Launch SynBio Innovation Accelerator

To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis , Inc. , they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 , including Codexis , Inc. ' expectations regarding its partnership with Casdin Capital and its investment in Arzeda Corp. .

Sources

3

Casdin Capital Team

1 Team Member

Casdin Capital has 1 team member, including current Founder, Chief Investment Officer, Eli Casdin.

Name

Work History

Title

Status

Eli Casdin

AllianceBernstein, Bear Stearns, and Cooper Hill Partners

Founder, Chief Investment Officer

Current

Name

Eli Casdin

Work History

AllianceBernstein, Bear Stearns, and Cooper Hill Partners

Title

Founder, Chief Investment Officer

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.